

May 31, 2016

To
The Dy. General Manager
Dept. of Corporate Affairs
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001.

Dear Sir/Madam,

Sub: Glenmark Pharmaceuticals Limited (Company) announces the launch of a proposed issue of Resettable Onward Starting Equity-linked Securities due 2022 (FCCBs).

The Board of Directors of the Company at its meeting held on 29 October 2015 and the shareholders of the Company by way of a special resolution passed by way of Postal Ballot at the deemed Extra-Ordinary General Meeting held on 25 January 2016 approved raising of funds up to USD 500 million through issuance of securities including equity shares or equity linked securities, including through QIPs, convertible bonds, warrants, depository receipts. The outcome of the meeting of the Board of Directors was intimated to the BSE and NSE on 29 October 2015.

In furtherance of the above decisions, the Issuance Committee of the Company at its meeting held today has approved raising of up to USD 200 million through issuance of FCCBs to be listed on the Singapore Stock Exchange (**Issue**) and has decided to open/launch the Issue today i.e May 31, 2016. Further, the Regulatory Floor Price for conversion of the FCCBs shall be Rs. 861.84.


J.P. Morgan Securities Plc is the Sole Global Coordinator and Book Runner for the said Issue.

This notice is being issued by the Company for information purposes only and does not constitute an offer, solicitation or advertisement with respect to the purchase or sale of any security of the Company including FCCBs and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

You are requested to kindly take the same on record and oblige.

Thanking you.

Yours faithfully,
For **Glenmark Pharmaceuticals Limited**



Sanjay Kumar Chowdhary
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com